Yu Kasamatsu

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Yohei Doi, Masaya Hibino, Ryota Hase et al. · Antimicrobial Agents and Chemotherapy · 2020 · 238 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

DOCK2 is involved in the host genetics and biology of severe COVID-19

Ho Namkoong, Ryuya Edahiro, Tomomi Takano et al. · Nature · 2022 · 97 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Single-cell analyses and host genetics highlight the role of innate immune cells in COVID-19 severity

Ryuya Edahiro, Yuya Shirai, Yusuke Takeshima et al. · Nature Genetics · 2023 · 69 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Characteristics of hospitalized patients with COVID-19 during the first to fifth waves of infection: a report from the Japan COVID-19 Task Force

Shotaro Chubachi, Ho Namkoong, Hiromu Tanaka et al. · BMC Infectious Diseases · 2022 · 51 citations · Full text

Veterinary Medicine, Infectious Diseases, Internal Medicine +13

The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force

Qingbo S. Wang, Ryuya Edahiro, Ho Namkoong et al. · Nature Communications · 2022 · 49 citations · Full text

Life Sciences, Genetics, Infectious Diseases +16